Long-Term Data Shows Rare Disease Drug's Efficacy
Sanofi subsidiary Blueprint Medicines announced four-year data from a study of its drug AYVAKIT. The results, presented at the AAAAI Annual Meeting, show sustained benefit and long-term safety for patients with the rare disease indolent systemic mastocytosis.
Indolent systemic mastocytosis (ISM) is the most common form of a rare disease driven in over 95% of cases by a mutation in the KIT D816V gene. This genetic flaw causes the body to produce an excess of mast cells, a type of immune cell. The buildup of these abnormal mast cells in the skin, bone marrow, and gastrointestinal tract leads to a wide range of debilitating symptoms. Patients often experience everything from skin lesions and severe diarrhea to bone pain, "brain fog," and a heightened risk of life-threatening anaphylactic shock. AYVAKIT (avapritinib) is not a symptom-management drug but rather a targeted therapy that specifically inhibits the KIT D816V mutation. By blocking the signal from this mutated protein, the drug interrupts the chain reaction that leads to the uncontrolled proliferation of mast cells. The new four-year data from the PIONEER study demonstrates the drug's long-term tolerability, with only a 3% discontinuation rate due to treatment-related adverse events. The study also highlighted specific improvements; for instance, patients with frequent diarrhea at the study's start saw a median reduction of 65.6% in its frequency. Beyond symptom control, the results suggest the drug has disease-modifying effects. Patients treated with AYVAKIT for three years showed increased bone mineral density in
